Joseph A. DiMasi

Joseph A. DiMasi publication distribution in Economics and Finance in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Economics and Finance in 2026. The highlighted bar marks where Joseph A. DiMasi sits on this spectrum.

Joseph A. DiMasi D-index placement in Economics and Finance in 2026

The chart shows the D-index (discipline H-index) distribution of Economics and Finance scientists ranked by Research.com in 2026. The highlighted bar marks where Joseph A. DiMasi sits on this spectrum.

Best Publications

• The price of innovation: new estimates of drug development costs

  Joseph A. DiMasi;Ronald W. Hansen;Henry G. Grabowski

  6402
  Citations

• Innovation in the pharmaceutical industry: New estimates of R&D costs

  Joseph A. DiMasi;Henry G. Grabowski;Ronald W. Hansen

  3552
  Citations

• Cost of innovation in the pharmaceutical industry.

  Joseph A DiMasi;Ronald W Hansen;Henry G Grabowski;Louis Lasagna

  1164
  Citations

• Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs

  J A DiMasi;L Feldman;A Seckler;A Wilson

  1048
  Citations

• The cost of biopharmaceutical R&D: is biotech different?

  Joseph A. DiMasi;Henry G. Grabowski

  843
  Citations

• Risks in new drug development: approval success rates for investigational drugs.

  Joseph A. DiMasi

  619
  Citations

• Economics of New Oncology Drug Development

  Joseph A. DiMasi;Henry G. Grabowski

  451
  Citations

• Returns on Research and Development for 1990s New Drug Introductions

  Henry Grabowski;John Vernon;Joseph A. DiMasi

  443
  Citations

• Pharmaceutical Innovation in the 21st Century: New Drug Approvals in the First Decade, 2000–2009

  KI Kaitin;JA DiMasi

  433
  Citations

• New drug development in the United States from 1963 to 1999.

  Joseph A. DiMasi

  326
  Citations

• The value of improving the productivity of the drug development process: faster times and better decisions.

  Joseph A. DiMasi

  309
  Citations

• Success rates for new drugs entering clinical testing in the United States

  Joseph A. DiMasi

  245
  Citations

• The economics of follow-on drug research and development

  Joseph A. DiMasi;Cherie Paquette

  236
  Citations

• Clinical Approval Success Rates for Investigational Cancer Drugs

  J A DiMasi;J M Reichert;L Feldman;A Malins

  230
  Citations

• Assessing the Financial Value of Patient Engagement: A Quantitative Approach from CTTI's Patient Groups and Clinical Trials Project.

  Bennett Levitan;Kenneth Getz;Eric L. Eisenstein;Michelle Goldberg

  161
  Citations

• Research and development costs for new drugs by therapeutic category. A study of the US pharmaceutical industry.

  Joseph A. DiMasi;Ronald W. Hansen;Henry C. Grabowski;Louis Lasagna

  159
  Citations

• R&D Costs and Returns by Therapeutic Category

  Joseph A DiMasi;Henry G Grabowski;John M Vernon

  151
  Citations

• The economics of follow-on drug research and development: trends in entry rates and the timing of development.

  Joseph A. DiMasi;Cherie Paquette

  146
  Citations

• The Cost of Drug Development

  Joseph A DiMasi;Henry G Grabowski;Ronald W Hansen

  142
  Citations

• Drug development costs when financial risk is measured using the Fama–French three‐factor model

  John A. Vernon;John A. Vernon;Joseph H. Golec;Joseph A. Dimasi

  134
  Citations